A phase III, randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare the efficacy and safety of GW873140 [aplaviroc] 400mg BID in combination with a ritonavir-containing optimized background therapy (OBT) regimen versus placebo plus OBT over 48 weeks.
Phase of Trial: Phase III
Latest Information Update: 18 Sep 2014
At a glance
- Drugs Antiretrovirals; Aplaviroc
- Indications HIV infections
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 26 Jan 2006 New trial record.